- Lithium and Valproate in Bipolar Disorder: From International Evidence-based Guidelines to Clinical Predictors
-
Crapanzano C, Casolaro I, Amendola C, Damiani S
- KMID: 2532800
- Clin Psychopharmacol Neurosci.
- 2022 Aug;20(3):403-414.
- doi: 10.9758/cpn.2022.20.3.403
Since decades, lithium and valproate remain the pharmacological cornerstone to treat bipolar disorder. Different response patterns occur according to the phases of illness. At same time, individual pretreatment variables may... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Olanzapine in Anxiety Dimension of Schizophrenia: A Systematic Review of Randomized Controlled Trials
-
Crapanzano C, Casolaro I, Damiani S, Amendola C
- KMID: 2536470
- Clin Psychopharmacol Neurosci.
- 2022 Nov;20(4):592-599.
- doi: 10.9758/cpn.2022.20.4.592
Anxiety symptoms and anxiety disorders are frequent in patients with schizophrenia and are associated with greater severity of both positive and negative symptoms, cognitive impairment, poorer functioning and quality of... -
- CITED
-
- Close
- SHARE
-
- Close
- Quetiapine Treatment for Post-traumatic Stress Disorder: A Systematic Review of the Literature
-
Crapanzano C, Damiani S, Casolaro I, Amendola C
- KMID: 2539649
- Clin Psychopharmacol Neurosci.
- 2023 Feb;21(1):49-56.
- doi: 10.9758/cpn.2023.21.1.49
Paroxetine and Sertraline are the only medications approved in posttraumatic stress disorder (PTSD). However, about 60% of traumatized patients fail to show an adequate clinical response. Second generation antipsychotics are... -
- CITED
-
- Close
- SHARE
-
- Close
